+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Glioblastoma Resistance to Chemotherapy: Molecular Mechanisms and Innovative Reversal Strategies. Cancer Sensitizing Agents for Chemotherapy Volume 15

  • Book
  • June 2021
  • Elsevier Science and Technology
  • ID: 5146450

Glioblastoma Resistance to Chemotherapy: Molecular Mechanisms and Innovative Reversal Strategies brings current knowledge from an international team of experts on the science and clinical management of glioblastoma chemoresistance. The book discusses topics such as molecular mechanisms of chemoresistance, experimental models to study chemoresistance, chemoresistance to drugs other than Temozolomide, and specific strategies to reverse chemoresistance. Additionally, it encompasses information on how to mitigate chemoresistance by targeted enhancement of p53 function. This book is a valuable resource for cancer researchers, oncologists, neuro-oncologists and other members of the biomedical field.

Glioblastoma (GBM) is the most invasive and malignant primary brain tumor in humans with poor survival after diagnosis, therefore it is imperative that molecular and cellular mechanisms behind therapy resistant GBM cells, as well as the therapeutic strategies available to counter the resistance are comprehensively understood.

Please Note: This is an On Demand product, delivery may take up to 11 working days after payment has been received.

Table of Contents

1. Overview of glioblastoma biological hallmarks and molecular pathology

2. Past and present drug treatments for glioblastoma

3. Investigational new drugs against glioblastoma

4. Molecular mechanimsms in temozolomide-resistant glioblastoma

5. Glioma stem cells and associated molecular mechanisms in Glioblastoma

6. Signaling in the tumor microenvironment of therapy-resistant glioblastoma

7. Intratumoral heterogeneity associated with glioblastoma drug response and resistance

8. Role of apoptosis, autophagy, and the unfolded protein response in glioblastoma chemoresistance

9. Role of multidrug resistance in glioblastoma chemoresistance: Focus on ABC transporters

10. Role of mitochondrial reactive oxygen species in glioblastoma drug resistance and strategies for therapeutic interventions

11. Glioblastoma cell-induced immunosuppression causing chemoresistance

12. Role of cell quiescence in glioblastoma cytotoxic resistance and strategies for therapeutic intervention

13. The molecular and cellular effects of radiotherapy-induced microenvironment changes on potential chemoresistance in glioblastoma

14. Molecular and cellular mechanism in recurrent glioblastoma chemoresistance

15. Role of long noncoding RNAs in temozolomide-resistant glioblastoma

16. Mechanisms of glioblastoma resistance to antiangiogenic agents and reversal approaches

17. Treatment and resistance of glioblastoma to CAR T-cell immunotherapies

18. On chip analysis of glioblastoma cell chemoresistance

19. Three-dimensional in vitro models to study potentiation of glioblastoma resistance by hypoxia

20. Chemoresistance mechanisms in mouse models of glioblastoma

21. Therapeutic approaches to overcome temozolomide resistance in glioblastoma

22. Understanding signal transduction pathways to overcome targeted therapy resistance in glioblastoma

23. Targeting the molecular mechanisms of glioma stem cell resistance to chemotherapy

24. Immunotherapy for glioblastoma as a means to overcome resistance to standard therapy

25. Role of microRNA therapy in presensitizing glioblastoma cells to temozolomide treatment

26. Drug penetration through the blood-brain barrier after radiotherapy: New approaches to bypass glioblastoma chemoresistance

27. Nanoparticles beyond the blood-brain barrier for glioblastoma

28. Small molecules targeting misfolded mutants of p53 as a rescue strategy to improve glioblastoma chemotherapy

29. p53 supplementation as a targeted cancer gene therapy for glioblastoma


Ramasamy Paulmurugan Associate Professor, Molecular Imaging Program at Stanford, and Department of Radiology, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, USA. Dr. Paulmurugan has expertise in molecular imaging, pre-clinical cancer imaging, cancer biology, nanotechnology, and molecular biotechnology. Tarik F. Massoud Professor, Molecular Imaging Program at Stanford, and Department of Radiology, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, USA. Dr. Massoud has expertise in molecular imaging, translational cancer imaging, neuro-oncology, and applications and perspectives relevant to clinical cancer management of glioblastoma patients.